Business Context and Reporting Period
This Form 6-K filing by Psyence Biomedical Ltd. covers the month of February 2026. The report discloses the resolution of a direct shareholder claim and related litigation initiated by the KAOS Group (KAOS Capital Ltd. and Adam Arviv) in the Ontario Superior Court of Justice.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed relates to the settlement of the litigation:
- Settlement Payment: $1,500,000 USD to be paid to KAOS.
- Share Transaction: KAOS agreed to sell 50,220 shares of common stock to a third party designated by the Company at $5.00 USD per share.
Material Changes
The primary material change is the execution of a Settlement Agreement on February 9, 2026. This agreement resolves all claims between the Company and the KAOS Group. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Management Commentary: The Company has finalized a full and final settlement to resolve the ongoing litigation.
Risks and Contingencies: The filing addresses the resolution of a legal contingency. No forward-looking guidance or outlook regarding future operations or financial performance is provided in this document.
Unusual Items: The $1,500,000 USD settlement payment represents a specific, non-recurring cash outflow associated with the legal resolution.
Investor Verification Checklist
- Verify the Company's current cash position to confirm the ability to fund the $1,500,000 USD settlement payment.
- Confirm the identity of the third-party buyer for the 50,220 shares and the timing of the share transfer.
- Review the full text of the Settlement Agreement (Exhibit 10.1) for any additional covenants or conditions not summarized in the filing.
- Check for any subsequent press releases or filings regarding the impact of this settlement on the Company's capital structure.